1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. ROR


The retinoic acid-related orphan receptor (ROR) subgroup of nuclear receptors consists of three members, RORα, -β and -γ (NR1F1-3 or RORA-C). RORs regulate several important physiological processes and have been implicated in a number of pathologies. RORα is critical for cerebellar development and bone formation, while RORβ regulates functions in the brain and retina. RORγ plays a key role in lymph node development and thymopoiesis. Furthermore, both RORα and RORγ are involved in regulating various metabolic pathways, inflammatory responses and immune functions, including Th17 cell differentiation.

The retinoic acid receptor-related orphan receptors α and γ (RORα and RORγ), are key regulators of helper T (Th)17 cell differentiation, which is involved in the innate immune system and autoimmune disorders. RORα/γ are members of the nuclear hormone receptor superfamily, which contains a signature type II zinc finger DNA binding motif and a hydrophobic ligand binding pocket.

ROR Related Products (30):

Cat. No. Product Name Effect Purity
  • HY-104037
    Cintirorgon Agonist 99.95%
    Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival.
  • HY-14413
    SR3335 Antagonist 98.02%
    SR3335 is a selective RORα inverse agonist that directly binds to RORα with a Ki of 220 nM.
  • HY-14422
    SR1078 Agonist 99.83%
    SR1078 is an agonist of retinoic acid receptor-related orphan receptor α/γ (RORα/RORγ).
  • HY-N0155
    Nobiletin Agonist 99.04%
    Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a retinoid acid receptor-related orphan receptors (RORs) agonist. Nobiletin can reduce reactive oxygen species (ROS) levels in differentiated C2C12 myotubes and has anti-inflammation and anti-cancer properties, including anti-angiogenesis, anti-proliferation, anti-metastasis and induced apoptosis.
  • HY-120384
    AZD-0284 Antagonist 99.92%
    AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.
  • HY-117819
    TMP920 Antagonist 99.88%
    TMP920 is a highly potent and selective RORγt antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC50 of 0.03 μM.
  • HY-130243
    RORγt Inverse agonist 6 Antagonist
    RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the treatment of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo.
  • HY-133128
    FM26 Antagonist
    FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells.
  • HY-13421
    SR1001 Inhibitor 99.79%
    SR1001 is a selective RORα and RORγt inverse agonist with Kis 172 and 111 nM, respectively.
  • HY-12776
    GSK805 Inhibitor
    GSK805 is a potent, orally bioavailable, and CNS penetrant RORγt inhibitor with pIC50 of 8.4 and >8.2 for RORγ FRET assay and Th17 assay.
  • HY-19770
    GSK2981278 Antagonist 99.70%
    GSK2981278 is a potent and selective RORγ inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding.
  • HY-16998
    SR2211 Antagonist >98.0%
    SR2211 is a potent, selective synthetic RORγ modulator and functions as an inverse agonist, with a Ki of 105 nM and an IC50 of ~320 nM.
  • HY-101454
    SR0987 Agonist 99.56%
    SR0987, a SR1078 analog, is a RORγt agonist, with an EC50 of 800 nM. SR0987 increases IL17 expression while repressing the expression of PD-1.
  • HY-112706
    PF-06747711 Antagonist 99.48%
    PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC50 of 4.1 nM. Anti-skin inflammatory activity.
  • HY-128604
    XY101 Inhibitor 98.88%
    XY101 is a potent, selective, metabolically stable and orally available RORγ inverse agonist with an IC50 of 30 nM and a Kd of 380 nM.
  • HY-19775
    GNE-6468 Inhibitor 99.50%
    GNE-6468 is a potent and selective RORγ(RORc) agonists with an EC50 value of 13 nM for HEK-293 cell.
  • HY-126321
    RORγt agonist 1 Agonist
    RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy.
  • HY-111748
    RORγt Inverse agonist 2 Antagonist
    RORγt Inverse agonist 2 is a selective, orally active RORγt inverse agonist with an EC50 of 119 nM.
  • HY-128573
    RORγt Inverse agonist 3 Antagonist
    RORγt Inverse agonist 3 is a potent, selective and orally active RORγ inverse agonist, with EC50s of 0.22 μM and 0.15 μM for hRORγ and RORγt (human IL-17 cells), respectively.
  • HY-111509
    TAK-828F Antagonist
    TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.